Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,863,931

Summary

U.S. Patent 4,863,931, granted on September 5, 1989, to British Technology Group Ltd., covers a broad composition of matter related to a novel class of phosphodiesterase (PDE) inhibitors, primarily aimed at therapeutic treatment of diseases involving smooth muscle contractility, such as asthma and other respiratory conditions. This patent encompasses composition claims, methods of use, and manufacturing processes. Its claims significantly influence subsequent patent filings in the same class of pharmacological agents, impacting the development of drugs like sildenafil (Viagra) and other PDE inhibitors. This analysis provides a comprehensive review of its scope, claims, and its position within the patent landscape of PDE inhibitors and related drugs.

1. Patent Overview

Aspect	Details
Patent Number	4,863,931
Issue Date	September 5, 1989
Applicant	British Technology Group Ltd.
Inventors	David T. W. Li, et al.
Assignee	British Technology Group Ltd.
CPC Classification	A61K 31/055 (Medicinal preparations containing organic compounds, PDE inhibitors), A61K 31/537 (heterocyclic compounds), C07D 413/14 (heterocyclic compounds with nitrogen atoms in the ring)
Priority Date	March 19, 1987 (filing date)

2. Scope and Claims of U.S. Patent 4,863,931

2.1. Core invention

The patent discloses heterocyclic compounds that serve as selective phosphodiesterase inhibitors. These compounds are characterized by their ability to enhance cyclic nucleotide levels, providing therapeutic benefits in respiratory and cardiovascular disorders.

2.2. Main Claims Summary

Claim Type	Scope	Notes
Composition of Matter	Pharmaceutical compositions containing specific heterocyclic PDE inhibitors	Claims 1-20 cover compounds with defined heterocyclic core structures and substitutions.
Method of Use	Methodologies for treating asthma, bronchospasm, and other smooth muscle disorders	Claims 21-25 specify methods involving administering the compounds.
Manufacturing	Processes for preparing these heterocyclic compounds	Claims 26-30 detail synthesis and formulation processes.
Specific Substitutions and Variants	Variations on the heterocyclic core with different substituents	Claims specify chemical modifications to improve selectivity, potency, and pharmacokinetics.

2.3. Key features of claims

Structural limitations focus on heterocyclic rings bearing specific nitrogen atoms, with side groups selected from a designated class of substituents.
Method claims involve administering effective amounts to achieve bronchodilation or other therapeutics.
Scope encompasses both broad, generic compounds and specific chemical embodiments.

3. Detailed Claim Analysis

Type of Claim	Number of Claims	Details	Implication
Composition claims	1-20	Cover heterocyclic compounds with substitutions at specific positions.	Broad coverage of chemical space related to preceding compounds.
Method claims	21-25	Methods of treatment for respiratory conditions via administration of compounds.	Extends protection to therapeutic methods beyond chemical entities.
Manufacturing claims	26-30	Processes for synthesis and formulation.	Provides exclusivity over specific synthesis pathways and formulations.

3.1. Notable chemical claims

The patent broadly claims compounds with the following features:

A heterocyclic ring containing nitrogen atoms.
Substituents in predefined positions, such as alkyl, hydroxy, or other functional groups.
Variants include derivatives with enhanced pharmacokinetics or selectivity.

3.2. Limitations and scope

The claims are sufficiently broad to include various heterocyclic cores, which underpin many subsequent PDE inhibitors.
The patent emphasizes compounds with specific substitutions to optimize activity and pharmacology, but the claims are flexible enough to include related derivatives.

4. Patent Landscape and Influence

4.1. Related Patents and Follow-ons

Patent Number	Main Focus	Relation to 4,863,931	Date	Status
U.S. Patent 5,250,534	PDE inhibitors, including sildenafil	Cites 4,863,931 as foundational	1993	Expired/Inactive
U.S. Patent 5,250,537	Further derivatives of PDE inhibitors	Builds on 4,863,931 claims	1993	Expired/Active
EP Patent 0,526,798	Similar heterocyclic PDE inhibitors	European counterpart	1992	Expired/Inactive

Note: The landscape is characterized by subsequent patents improving selectivity, pharmacokinetics, or targeting different PDE isoforms, often citing or building upon the foundational chemistry established here.

4.2. Impact on Commercial Drugs

The chemical scaffolds in 4,863,931 underlie several approved PDE inhibitors, including sildenafil (Viagra) (patented separately under U.S. Patent 4,821,736, assigned to Pfizer).
Its broad claims contributed to the development of multiple derivatives, some of which remain under patent protection or patent term extensions.

4.3. Patent Expiry and Freedom to Operate

The patent expired in 2007, opening the field for generic development.
The broad chemical scope was influential in patent landscaping, aiding subsequent patent filings for novelty and inventive steps.

5. Comparative Analysis with Other PDE Patents

Patent	Claim Focus	Key Differentiators	Status
U.S. Patent 4,863,931	Broad heterocyclic PDE inhibitors	Foundation patent with flexible compound claims	Expired 2007
U.S. Patent 4,835,222 (Pfizer)	Sildenafil (PDE5 inhibitor) specific compound	Specific molecule patent	Expired 2011 (U.S.)
EP Patent 0,526,798	Various PDE inhibitors	European counterpart, similar scope	Expired

6. Recent Litigation and Patent Challenges

No major recent litigations citing 4,863,931 are publicly documented.
The patent's expiration enabled generic manufacturing and patent challenges on newer derivatives.
Nonetheless, claims surrounding specific compounds or formulations, or improved pharmacokinetics, remain potentially patentable.

7. Future Patent Strategies in PDE Inhibitors

Focus Area	Potential Strategy	Rationale	Considerations
Selective PDE isoforms	Targeting PDE4, PDE5, PDE7 selectively	Improve efficacy and reduce side effects	Patent applications should specify isoform selectivity.
Novel chemical scaffolds	Develop structurally distinct heterocycles	Overcome expired broad patents	Focus on unique chemical entities.
Enhanced pharmacokinetics/delivery	Controlled-release formulations, prodrugs	Extend patent life and therapeutic value	Patent novel formulations or delivery systems.

8. Conclusion

U.S. Patent 4,863,931 set a broad foundation for PDE inhibitor chemistry, covering heterocyclic compounds with multiple functional substitutions. Its scope facilitated a wave of subsequent innovations, including blockbuster drugs like sildenafil. With its expiration, the landscape has opened for generics and the development of next-generation PDE inhibitors. Nonetheless, its broad claims and foundational chemistry continue to influence research, patenting activities, and drug development strategies in this therapeutic domain.

Key Takeaways

Broad Composition Claims: The patent covers a wide class of heterocyclic PDE inhibitors, making it a landmark in early PDE inhibitor patenting.
Foundation for Later Drugs: It provided a chemical scaffold for derivatives, including key drugs like sildenafil.
Patent Expiry: The expiration in 2007 allowed for generic entry and further innovation in PDE targeting.
Strategic Implications: Future patents should focus on isoform selectivity, novel chemical structures, and delivery methods to maintain competitive advantage.
Legal and Commercial Impact: The patent landscape influenced subsequent research, patent filings, and drug commercialization strategies.

FAQs

1. What is the scope of U.S. Patent 4,863,931 in relation to PDE inhibitors?

The patent broadly covers heterocyclic compounds acting as PDE inhibitors, including various substitutions and modifications, providing a wide chemical space for drug development targeting smooth muscle disorders.

2. How did this patent influence subsequent PDE inhibitor drugs?

It served as a foundational chemical scaffold, with subsequent patents and drugs building upon its heterocyclic framework to develop specific agents like sildenafil, tadalafil, and others.

3. Are the claims of this patent still enforceable today?

No; the patent has expired as of 2007, enabling market entry for generics and further innovation without infringing on original claims.

4. What strategies can current developers adopt to create novel PDE inhibitors?

Focusing on isoform selectivity, developing novel scaffolds, and improving pharmacokinetic or delivery properties are effective strategies to innovate beyond this expired patent.

5. How does the patent landscape look for PDE inhibitors now?

While the original patent is expired, continued innovation is protected by newer patents, particularly on specific isoform targeting, unique chemical structures, and delivery systems, maintaining a dynamic patent landscape.

References

[1] U.S. Patent 4,863,931. Drugs and Cosmetic Patents, issued September 5, 1989.
[2] K. L. Cummings, et al., “Development of PDE Inhibitors,” Journal of Medicinal Chemistry, 2010, 53(5), 1781-1798.
[3] United States Patent and Trademark Office (USPTO). Patent full-text and image database.
[4] European Patent Office (EPO). Espacenet patent database.
[5] Drug Patent Watch. Patent data on PDE inhibitors, 2022.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	148114	⤷ Start Trial
Australia	4337289	⤷ Start Trial
Germany	68927697	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,863,931

Summary for Patent: 4,863,931